INTRODUCTION
In nature, innumerable biochemical reactions occur in perfect balance to aid the life processes of unicellular as well as multicellular organisms. The availability of nutrients is a prerequisite for these unbiased progressions of life. Although ready availability of all nutrients may seem to be an ideal scenario, their regulation is the key to establish control over the complex multitude of interconnected biochemical cycles. Besides, several micronutrients can be toxic if present in higher concentrations than required. These environmental observations are clearly reflected in the growth cycle of micro-organisms due to the simplicity of their cellular structures. For instance, iron is a vital micronutrient present abundantly in nature, yet its availability is limited for acquisition by microorganisms (Saha et al., 2013). Iron undergoes oxidation from Fe$^{2+}$ to Fe$^{3+}$ to form an insoluble ferric oxyhydroxide, under normal environmental conditions (neutral pH and presence of oxygen), which cannot be utilized for any cellular processes by microorganisms.
The uptake of iron is further regulated with several repressor proteins identified in gram negative as well as gram positive bacteria (Visca & Imperi, 2018). These strict regulations are necessary since the free ferric form of iron is toxic and its increased uptake may inhibit microbial growth.

The above perspective leads to logical reasoning that iron requirement for optimal bacterial growth, i.e., approximately $10^{-6}$ to $10^{-7}$ M, shall be met by a suitable biochemical tool that functions under another strictly regulated mechanism (Brandel et al., 2012). This requirement is fulfilled with the help of siderophores. They are compounds secreted by bacteria, fungi and plants under iron-starvation conditions, which are capable of scavenging insoluble forms of iron in the environment to form soluble iron complexes. They are low molecular weight compounds with very high affinity for iron, and hence act as natural iron chelators (Jenifer & Sharmili, 2015 & Krewulak & Vogel, 2008). Siderophores use negatively charged oxygen groups as donors to form strong complexes with iron which is transported in the periplasm through unique Outer Membrane Proteins (OMPs) or Siderophore Binding Proteins (SBPs) on the bacterial cell membrane. Many such OMPs and SBPs have been characterized in gram negative and gram positive bacteria respectively (Schalk et al., 2009 & Fukushima et al., 2014).

The importance of siderophores can be understood by discerning the indispensable role of iron in metabolic processes. The microstructure of iron shows properties of plasticity, and exhibit excellent co-ordination and redox potential. These are essential features for binding of molecules to diverse ligands. Iron acquires a central position in the structure of hemoglobin and myoglobin, in eukaryotes. Moreover, all fundamental life processes in prokaryotes as well as eukaryotes viz., respiration, photosynthesis, nitrogen fixation and ATP synthesis, driven by electron transport chain, cofactors and other essential enzymatic reactions require iron containing proteins (Ali & Vidhale, 2013). Over 100 enzymes have been identified and reported in the literature, which possesses iron containing cofactors (Chincholkar et al., 2000).

From an evolutionary point of view, siderophores also played a characteristic role. During early evolution, siderophores were majorly responsible for developing iron homeostasis to prevent Fenton induced radical damage. The stringent requirement of these molecules for survival, pathogenicity and suppression of host defense mechanisms is also well documented (Albelda-Berenguer et al., 2019). Recently there are interesting reports on the ability of bacteria and fungi to utilize siderophores (from other microorganisms) without its production (Butaitė et al., 2017). It has also been suggested that they may play a role in cell communication, virulence and oxidative stress (Johnstone & Nolan, 2015).

Siderophores show a wide range of applications in agriculture, bioremediation, conservation of cultural artifacts and medicine. This review, however, limits its scope and focuses on types and mechanism of bacterial siderophores, and their potential application in the field of medicine.

**Mechanism of siderophores**

The mechanism of iron uptake in bacteria operates with the help of a multi-component system. The detailed mechanism is outlined in Figure 1. These systems include siderophores, OMPs like Fec A, Fep A, transport protein complex like TonB-ExbB-ExbD, periplasmic binding protein and an inner membrane ATP-dependent Fec CDE-Fep CDE protein. Under iron starvation conditions, siderophores are synthesized along with various receptor molecules and secreted in the surrounding environment. These siderophores bind with iron to form siderophore-iron complex which is identified and transported through OMPs in the periplasm. It is then transported through the ABC-transporter systems i.e., Fec C, D, E and Fep C, D, E from ATP-binding cassette into the cytoplasmic membrane. One of these proteins act as a permease and spans the cytoplasmic membrane, whereas the other protein hydrolyses ATP to provide energy for transport of siderophore-iron complex towards the inner membrane of cytoplasm. This
complex is released inside the cytoplasm with the help of membrane protein Ton B. Although the exact mechanism of release of iron from the complex is still unknown, it is suggested to occur as a result of hydrolytic action on siderophore molecule. Another possible mechanism may be the reduction of Fe$^{3+}$ by NAD (P) H linked siderophore reductase to form low affinity Fe$^{2+}$ molecules which can be dissociated from the complex (Ali & Vidhale, 2013).

*Fig. 1: Mechanism of siderophore mediated iron transport in bacteria (Adapted from Ali and Vidhale 2013)*

**Types of Siderophores**

Siderophores are characterized, based on their functional groups and oxygen ligands for Fe (III) coordination, into three main categories i.e., hydroxamates, catecholates and carboxylates. However, certain bacteria produce siderophores containing mixed functional groups. Figure 2 represents the structures of common siderophores from these categories. Over 500 natural iron chelating compounds are identified till date and over 270 have been structurally characterized (Ahmed & Holmstrom, 2014). Few examples of diverse siderophores produced by microorganisms are indicated in Table 1. Among the different types of siderophores, the occurrence of catecholates is more common in bacteria as compared to carboxylates and hydroxamates. Fungi, on the other hand, predominantly produce hydroxamate type of siderophores (Stintzi & Raymond, 2000). Their structure may possess bidentate to hexadentate chelation sites and the increase in this denticity is associated with higher affinity for iron. Factors like cyclization of di-, tetra- and hexadentate siderophores further enhance the chemical stability, and improve resistance to degrading enzymes (Ahmed & Holmstrom, 2014).
Hydroxamate siderophores

Hydroxamate siderophores have a molecular formula of C (=O) -N-(OH) R, where R is either an amino acid or its derivative. They show a higher affinity for ferric iron and thus protect the siderophore-iron complex against hydrolysis and enzymatic degradation in the environment (Winkelmann, 2007). Several methods of detecting hydroxamate siderophores include Neilands spectrophotometric assay, electrospray ionization mass spectrometry (ESI-MS), Modified overlaid chrome azurol S (O-CAS) assay and Csaky’s assay (Neilands, 1981; Gledhill, 2001; Perez-Miranda et al., 2007; & Pal & Gokarn, 2010).

Table I: Siderophores produced by micro-organisms

| Type                      | Siderophore producer                  | Example                        | Reference                      |
|---------------------------|---------------------------------------|--------------------------------|--------------------------------|
| Catecholates              | Enterobacteria                        | Enterobactin                    | Poole et al. 1990              |
|                           | Salmonella sp.                        | Salmochelin (glycosylated-derivative) | Hantke et al. 2003            |
|                           | Bacillus sp.                          | Bacillicactin                   | Miethe et al. 2006             |
| Carboxylates              | Rhizobium sp.                         | Rhizobactin                     | Smith et al. 1985              |
|                           | Azoarcus sp.                          | Azoarcus                       | Dorchelt et al. 1995           |
|                           | Shewanella frisoni DSM 20459          | Staphylofrein A (derivative of citric acid) | Mieries et al. 1990 |
| Hydroxamates              | Actinobacter sp.                      | Ferrioxamine E                  | Ahmed and Hofmisten 2015       |
|                           | Actinobacter sp.                      | Ferrioxamine E                  | Ahmed and Hofmisten 2015       |
|                           | Trochoderma sp.                       | Coprogen                        | Mauro and Keller-Schierlein 1968|
|                           | Flavobacterium                      | Fusigen                         | Zahn et al. 1963               |
|                           | Streptomyces sp.                      | Desferrioxamine                 | Dickmann and Zahn 1967        |
| Mixed (phenolate, thioate, oxazoline and carboxylate) | Yersinia pestis                     | Yersinicolactoner               | Sebbane et al. 2010           |
| Mixed (oxazoline rings and catechol groups) | Paracoccus denitrificans              | Parabactin                      | Bergren and Wemert 1990       |
| Mixed (hydroxamate and carboxylate moieties) | Mesorhizobium lindenieri             | Mucobactin                      | Mira et al. 2019              |
|                           | Pseudomonas sp.                      | Pijoseline                      | Leong and Neilands 1982       |
|                           | Enterobacteria                       | Aerobactin                      | Guo et al. 2012               |
|                           | Erwinia carotovora                   | Aerobactin                      | Ishimaru and Loper 1992       |
| Mixed (catechol and carboxylate moieties) | Mycobacterium Hydrocarbonolicose     | Pterobactin                     | Hickford et al. 2004          |
| Mixed (hydroxyphenyl-thiazolinyl-carboxylate) | Pseudomonas aeruginosa              | Pseudochelin                    | Brandel et al. 2012           |
| Cyclic                    | Enterobacteria                        | Enterobactin                    | Dertz et al. 2006             |
|                           | Streptomyces pilosus                 | Ferrioxamine E and Rhodoturilic acid | Muller et al. 1984         |

Catecholate (phenolate) siderophores

As compared to hydroxamates, catecholates are produced by lesser number of bacteria (Dave et al., 2006). They show 2, 3 dihydroxy benzoyl units attached via an amide linkage in their molecular structure. This backbone structure can be polyamine, a peptide or a macrocyclic lactone. Siderophores with one, two or three catecholate or phenolate chelating groups attached to a peptide backbone have been reported. Enterochelin siderophore have been reported to show very high affinity to ferric ion and can detect minimalistic amounts of iron present in the environment (Dertz et al., 2006). In general, catecholates show highest affinity to ferric ion due to the formation of five-membered chelate rings. Similar to hydroxamates, Neilands spectrophotometric assay can also be used to detect catecholates by observing wine red coloration after binding to FeCl₃ during the assay and absorbance at 495nm (Neilands, 1981). Other methods like HPLC coupled with Diode Array Detection (DAD) and Electrospray Ionization Mass Spectroscopy (ESI-MS) are also reported to be helpful in detecting catecholate siderophores (Saha et al., 2016).

Carboxylate siderophore

This class of siderophore is largely produced by bacteria like Rhizobium sp., Staphylococcus sp. and fungi like Mucorales sp. Very few siderophores are characterized and reported to have an iron chelating moiety composed of only carboxylate and α-hydroxy donor groups (Hickford et al., 2004). One of the best characterized carboxylate siderophore is Rhizobactin produced by species Rhizobium meliloti strain DM4 (Smith & Neilands, 1984). They are considered to be less efficient than other siderophores, however, they are tolerant to acidic pH and hence useful for microbes living in acidic environments. There are various methods for detecting carboxylate siderophores. One such method is a
spectrophotometric assay to detect absorbance of siderophore copper complex between 190-280nm (Shenker et al., 1992). Similarly O-CAS assay, or Vogels chemical test can also be used for the detection of carboxylate siderophores (Perez-Miranda et al., 2007; Saha et al., 2016 & Vogel, 1987).

Medical applications of siderophores
Exploiting the metabolic activities of pathogens against their own propagation is one of the most intelligent applications of biotechnology. Siderophores and their substituted derivatives have been modified by using bactericidal conjugates and used as a drug delivery system to treat life threatening diseases. Few examples of such diseases include malaria, tuberculosis and cancer. It is also helpful in treating infections caused by Multi-Drug Resistant (MDR) bacteria, and diseases caused due to overload of iron in the body. Figure 3 represents the potential of siderophores in treating these infections. Three strategies are introduced to circumvent the iron dependence in pathogens with the help of siderophores. These include

1) Trojan horse strategies to facilitate cellular uptake of antibiotics
2) Artificial iron starvation by using antagonists of ferric ions
3) Inhibition of iron metabolic pathways

Siderophore mediated drug delivery for treatment of MDR bacteria
Of lately, one of the most critical challenges faced by the pharmaceutical industry is the increasing prevalence of antibiotic resistance among pathogens and the relatively limited discovery of new antibiotics. This challenge has been met by exploring the metabolic requirements of pathogens. Since the iron uptake is essential for the survival of pathogens, the iron-siderophore system has been exploited to deliver drugs inside the cells, instead of or along with iron (Saha et al., 2013).

In the Trojan horse strategy (Figure 4), siderophore-antibiotic conjugates can be produced synthetically with improved cell permeability and reduced susceptibility to resistance mechanisms. Antibiotics such as β-lactams, erythromycin, sulphonamides, spiramycin, vancomycin, nalidixic acid, norfloxacin, and antifungal agents like 5-fluorocytosine and neoenactins can be used in conjunction against pathogens. Once such conjugates are synthesized, the iron transport mechanisms can be directed to import the drugs into the cell. This strategy results in a remarkably effective drug delivery system since pathogens recognize the siderophore component as an iron delivery agent and assimilate the modified conjugate (with antibiotic). With an appropriate lethal dose of drugs, it immediately results in cell death (Budzikiewicz, 2001). Since the pathogenic cells do not survive, there is no way to design a defense mechanism, by pathogens, against this strategy. β-lactam drugs, as siderophore conjugates, have been used successfully to treat drug resistant infections (Carvalho et al., 2014). Similarly, gallium (a conjugate of iron) was successful in inhibiting biofilm formation by antibiotic resistant strains of P. aeruginosa (Reedy et al., 2007). This strategy is particularly effective in treatment of infections caused by P. aeruginosa, since they are often complex and associated with drug resistance. They show intrinsic mechanisms to resist many antibiotics. Moreover, they acquire drug resistance comparatively easily due to their narrower porin channels that act more effectively as an efflux pump for antibiotics (Tomaras et al., 2013). The use of the appropriate pyoverdin, as a transport vehicle, has also been advantageous for a species specific attack when conjugated with 2, 3-dihydroxybenzoic acid and 5-hydroxypyrid-4-one-3-carboxylic acid for drug resistant P. aeruginosa (Budzikiewicz, 2001). Sideromycins are another group of antibiotics employed in “Trojan horse” drug delivery strategy to enhance the therapeutic efficiency and overcome antibiotic resistance. Albomycin too displays a broad-spectrum antimicrobial activity (Pramanik et al., 2007).

Antimalarial activity of siderophores
Some siderophores exhibit antimalarial activity by showing a lethal effect on Plasmodium falciparum (Tsafack et al., 1996).
Few examples include, siderophores produced by *K. pneumoniae* and *Streptomyces pilosus* (Gysin et al., 1991 & Muller et al., 1984). Both in vivo and in vitro studies have indicated the efficacy of Desferrioxamine B in treating malaria by depleting the intracellular iron required for metabolic activity as well as pathogenicity of the parasite (Scott et al., 1990). Later this drug therapy was improved by conjugating Desferrioxamine B with Nalidixic acid to cause iron-catalyzed oxidative DNA damage and, in turn, treat malaria caused by MDR *P. falciparum* (Ghosh et al., 1995).

Iron overload therapy using siderophores
As indicated earlier in this review, the presence of iron above the optimal concentration can severely restrict the growth of an organism. Same is true for humans. In addition, several metabolic disorders can lead to overdose of iron in the circulatory system as well as organs, leading to deleterious effect of redox cycle by production of free radicals. Sickle cell disease and Thalassemia major are
genetic disorders characterized by sickle shaped red blood cells and haemoglobin abnormality respectively. The patients often require whole blood transfusion resulting in steady buildup of iron in the body. This is because there is no physiologically specific mechanism for the excretion of iron in humans. Other diseases like hemochromatosis causes a progressive increase in the iron content of the body and deposition in the liver, heart or pancreas. Haemosiderosis is secondary haemochromatosis caused by excessive blood transfusions, severe chronic haemolysis or iron intoxication. Collectively all these disorders are termed as iron overload disorders and require removal of iron from the body (Kontoghiorghes et al., 2005).

Siderophores are used for treatment of these disorders by employing a reverse strategy, where they are used as chelating agents to bind with iron in the circulatory system to form ferrioxamine. This enhances its elimination via urine. Hence acute iron intoxication and chronic iron overload disorders can be managed effectively. Interestingly, Desferrioxamine B has proved useful in removal of vanadium, toxic metals in dialyzed patients, and in iron overload therapy by using conjugates such as deferiprone (Ferriprox), deferasirox (Exjade) and deferitrin (Kontoghiorghes et al., 2005; Trivedi, 2016 & Ali & Vidhale, 2013).

Anticancer treatment using siderophores

The rapid cell division and metabolism in cancer cells increases their iron requirements. Consequently, the uptake and storage of iron in cancer cells are also higher. Moreover, the involvement of iron is observed in the microenvironment of tumor formation as well as metastasis. This implies the critical role of iron in tumor initiation and growth (Saha et al., 2016). These informations have been used to design siderophore mediated cancer therapy by artificial reprogramming of iron metabolism to disrupt its acquisition, efflux and storage (Torti & Torti, 2013). Derivatives of siderophores are used in cancer therapy coupled with synthetic iron chelators such as dexrazoxane and isonicotinoyl hydrazine in addition to Desferrioxamine B and mycobacterial desferrioxochelins (Chong et al., 2002 & Jayasinghe et al., 2015). Desferrioxamines was reported to significantly decrease the growth of aggressive tumors in patients with neuroblastoma (NB) and leukemia by inhibiting DNA replication (Buss et al., 2003). Several other siderophores such as dexrazoxane, O-trensox, desferrioxelchins, desferrithiocin and tachpyridine act as iron chelators in cancer therapy (Miethke & Marahiel, 2007). However, some siderophores are also useful in the clearance of non-transferrin-bound iron present in the serum which is seen in cancer therapy as a result of exposure to chemotherapy (Saha et al., 2016).

Anti-tuberculosis treatment using siderophores

Mycobacterium tuberculosis is a pervasive human pathogen which kills around 1.8 million people every year. The emergence of MDR and extensively drug-resistant strains of M. tuberculosis have been increasingly reported, and hence confounded attempts for immediate actions of disease control. Like other pathogens, iron acquisition is vital for the pathogenicity of M. tuberculosis. They acquire iron from the host using several strategies like secreting reductants, taking citrate as a carrier, utilizing a hemoglobin-haptoglobin complex and synthesizing hemolysins (Litwin & Calderwood, 1993). However, the role of siderophores remains indispensable for their virulence and proliferation. Hence, they produce siderophores called mycobactins and carboxymycobactins (McBride, 2012). A study supporting the requirement of siderophores for virulence characteristic of pathogens, described the growth impairment of Mycobacterium sp. in absence of mycobactin. These findings further indicated the necessity of these compounds for maintaining iron homeostasis and pathogenesis (Kobylarz, 2016). Thus these compounds can be a promising target for novel antibiotics. Mycobactin analogs and heterologous compounds, designed to overcome the impervious cell wall barrier which is
characteristic of Mycobacterium sp., can be utilized by *Mycobacterium aurum*. Hence they may aid in formulating novel drug vectors. Approaches have also been made for obtaining naturally occurring antibiotic conjugated siderophores, known as sideromycins. These biomimetic siderophores have shown considerable activity against *M. tuberculosis* (Wells et al., 2013). Similarly, synthetic approaches in another study illustrated the use of mycobactin-artemisinin conjugate, a synthetic analogue of mycobactin T which provides access to the pathogen’s cell, while artemisinin serves as the antibiotic pharmacophore (Kurth et al., 2016).

**Other medical applications of siderophores**
Siderophores are efficient metal chelators and hence are capable of mobilizing toxins like aluminum, gallium, uranium, vanadium, chromium, copper, lead, cadmium and manganese. Hence they are used for removal of transuranic elements from the body. Aluminum intoxication occurs in dialysis encephalopathy (Nagoba & Vedpathak, 2011). Similarly, the overload of other metals may occur in the human body as a result of intoxication, over-exposure, accidental ingestion etc. In such cases siderophores provide a safe treatment option by excretion of these metals in soluble forms from the body. Another interesting application of siderophores is clinical and translational imaging. This technique replaces the iron in siderophores with radionuclides like Gallium-68 to obtain live images of pathogenesis (Petrik et al., 2017). A recent study further reported the promising application of Zirconium-89, as a biomarker for radiotracer design and in vivo delivery, for clinical investigations of prostate cancer. They further indicated the use of metallic isotopes for nuclear imaging techniques like positron emission tomography may be effective for detection of cancers in generals (Cortezon-Tamarit et al., 2019).

**CONCLUSION**
The availability of iron is of paramount importance for the metabolic processes of micro-organisms. Their fundamental role of extracellular solubilization of iron from minerals or organic substances has been carefully maneuvered with the help of biotechnology to design strategies for the treatment of complicated diseases. They exhibit excellent potential for sustainable approaches in the field of medicine. Moreover, their scope is not limited and they find suitable application in ecological and environmental biotechnology, agriculture, metal recovery from ores and many more areas. Hence it is necessary to upgrade our literary cognition with more specialized studies to explore the currently unidentified microbial siderophores and the potential they offer.

**REFERENCES**
Ahmed, E., & Holmstrom, S. J. M. (2015). Siderophore production by microorganisms isolated from a podzol soil profile. *Geomicrobiol J.* 32(5), 397-411.

Ahmed, E., & Holmström, S. J. (2014). Siderophores in environmental research: roles and applications. *Microb. Biotechnol.* 7(3), 196-208.

Ali, S. S., & Vidhale, N. N. (2013). Bacterial siderophore and their application: A review. *Int. J. Curr. Microbiol. Appl. Sci.* 2(12), 303-312.

Albelda-Berenguer, M., Monachon, M., & Joseph, E. (2019). Siderophores: From natural roles to potential applications. *Adv. Appl. Microbiol.* 106, 193-218.

Bergeron, R. J., & Weimar, W. R. (1990). Kinetics of iron acquisition from ferric siderophores by *Paracoccus denitrificans*. *J. Bacteriol.* 172(5), 2650-2657.

Brandel, J., Humbert, N., Elhabiri, M., Schalk, I. J., Mislin, G. L. A., & Albrecht-Gary, A. M. (2012). Pyochelin, a siderophore of *Pseudomonas aeruginosa*: physicochemical characterization of the iron (iii), copper (ii) and zinc (ii) complexes. *Dalton Transact.* 41(9), 2820-2834.

Butaite, E., Baumgartner, M., Wyder, S., & Keummerli, R. (2017). Siderophore
cheating and cheating resistance shape competition for iron in soil and fresh water *Pseudomonas* communities. *Nature Communicat.* 8, 414.

Buss, J. L., Torti, F. M., & Torti, S. V. (2003). The role of iron chelation in cancer therapy. *Curr. Med. Chem. 10*(12), 1021-1034.

Budzikiewicz, H. (2001). Siderophore-antibiotic conjugates used as trojan horses against *Pseudomonas aeruginosa*. *Curr. Top. Med. Chem. 1*(1), 73-82.

Carvalho, C. C., De, C. R., & Fernandes, P. (2014). Siderophores as “Trojan Horses”: tackling multidrug resistance? *Front. Microbiol. 5*, 290.

Chincholkar, S. B., Chaudhari, B. L., Talegaonkar, S. K., & Kothari, R. M. (2000). Microbial iron chelators: A sustainable tool for the biocontrol of plant diseases. In: Upadhaya, R. K., MukerjiK, G., & Chamola, B. P. (eds.), Biocontrol potential and its exploitation in sustainable agriculture, New York; Kluwer Academic/Plenum Publishers, 49-70.

Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H. M., & Harris, A. L. (2002). A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. *Cancer Res. 62*(23), 6924-6927.

Cortezon-Tamarit, F., Baryzewska, A., Lledos, M., & Pascu, S. I. (2019). Zirconium-89 radio-nanochemistry and its applications towards the bioimaging of prostate cancer. *Inorganica Chimica Acta. 496*, 119041.

Dave, B. P., Anshuman, K., & Hajela, P. (2006). Siderophores of halophilic archaea and their chemical characterization. *Indian J. Exp. Biol. 44*(4), 340-344.

Dertz, E. A., Xu, J., Stintzi, A., & Raymond, K. N. (2006). Bacillibactin-mediated iron transport in *Bacillus subtilis*. *J. Am. Chem. Soc. 128*(1), 22-23.

Diekmann, H., & Zahner, H. (1967). Konstitution von Fusigen und dessen Abbau zu 2-Anhydro-mevalonsaurelacton. *Eur. J. Biochem. 3*(2), 213-218.

Drechsel, H., Tschierske, M., Thieken, A., Jung, G., Zahner, H., & Winkelmann, G. (1995). The carboxylate type siderophore rhizoferrin and its analogs produced by directed fermentation. *J. Ind. Microbiol. 14*, 105-112.

Fukushima, T., Allred, B. E., & Raymond, K. N. (2014). Direct evidence of iron uptake by the gram-positive siderophore-shuttle mechanism without iron reduction. *ACS Chem. Biol. 9*(9), 2092-2100.

Gao, Q., Wang, X., Xu, H., Xu, Y., Ling, J., Zhang, D., Gao, S., & Liu X. (2012). Roles of iron acquisition systems in virulence of extraintestinal pathogenic *Escherichia coli*: salmochelin and aerobactin contribute more to virulence than heme in a chicken infection model. *BMC Microbiol. 12*, 143.

Ghosh, M., Lambert, L. J., Huber, P. W., & Miller, M. J. (1995). Synthesis, bioactivity, and DNA-cleaving ability of desferrooxamine B- nalidixic acid and anthraquinone carboxylic acid conjugates. *Bioorg. Med. Chem. Lett. 5*(20), 2337-2340.

Gledhill, M. (2001). Electrospray ionisation-mass spectrometry of hydroxamate siderophores. *Analyst 126*(8), 1359-1362.

Gysin, J., Crenn, Y., Pereira Da Silva, L., & Breton C. (1991). Siderophores as anti-parasitic agents. *US Patent (US 5192807 A) 5*, 192-807.

Hantke, K., Nicholson, G., Rabsch, W., & Winkelmann, G. (2003). Salmochelins, siderophores of *Salmonella enterica* and uro-pathogenic *Escherichia coli* strains, are recognized by the outer membrane
receptor IroN. Proc. Nat. Acad. Sci. 100(7), 3677-3682.
Hickford, S. J. H., Kupper, F. C., Zhang, G., Carrano, C. J., Blunt, J. W., & Butler A. (2004). Petrobactin sulfonate, a new siderophore produced by the marine bacterium Marinobacter hydrocarbonoclasticus. J. Nat. Prod. 67(11), 1897-1899.
Ishimaru, C. A., & Loper, J. E. (1992). High-affinity iron uptake systems present in Erwinia carotovora subsp. carotovora include the hydroxamate siderophore aerobactin. J. Bacteriol. 174(9), 2993-3003.
Jayasinghe, S., Siriwardhana, A., & Karunaratne, V. (2015). Natural iron sequestering agents: their roles in nature and therapeutic potential. Int. J. Pharm. Pharm. Sci. 7(9), 8-12.
Jenifer, C. A., & Sharmili, A. S. (2015). Studies on siderophore production by microbial isolates obtained from aquatic environment. Eur. J. Exp. Biol. 5(10), 41-45.
Johnstone, T. C., & Nolan, E. M. (2015). Beyond iron: non-classical biological functions of bacterial siderophores. Dalton Trans. 44(14), 6320-6339.
Krewulak, K. D., & Vogel, H. J. (2008). Structural biology of bacterial iron uptake. Biochim Biophys Acta Biomembr. 1778(9), 1781-1804.
Kontoghiorghes, G. J., Eracleous, E., Economides, C., & Kolnagou, A. (2005). Advances in iron overload therapies: Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr. Med. Chem. 12(23), 2663-2681.
Kobylarz, M. J. (2016). Siderophore-mediated iron metabolism in Staphylococcus aureus. Thesis submitted to University of British Columbia.
Kurth, C., Kage, H., & Saha, N. M. (2016). Siderophores as molecular tools in medical and environmental applications. Org. Biomol. Chem. 14(35), 8212-8227.
Leong, S. A., & Neilands, J. B. (1982). Siderophore production by phytopathogenic microbial species. Arch. Biochem Biophys. 281(2), 351-359.
Litwin, C. M., & Calderwood, S. B. (1993). Role of iron in regulation of virulence genes. Clin. Microbiol. Rev. 6(2), 137-149.
Maurer, B. J., Keller-Schierlein, W., & Zhner, H. (1968). Ferribactin, a siderochrome from Pseudomonas fluorescens Migula: Arch. Microbiol. 60, 326-333.
Meiwes, J., Fiedler, H. P., Haag, H., Zahner, H., Konetschny-Rapp, S., & Jung, G. (1990). Isolation and characterization of Staphyloferrin A, a compound with siderophore activity from Staphylococcus hyicus DSM 20459. FEMS Microbiol. Lett. 67, 201-205.
McBride, N. S. (2012). Detection of Mycobacterial siderophores and implications for diagnostics. Thesis submitted to the University of Cambridge Queens’ College.
Miethke, M., Klotz, O., Linne, U., May, J. J., Beckering, C. L., & Marahiel, M. A. (2006). Ferri-bacillibactin uptake and hydrolysis in Bacillus subtilis. Mol. Microbiol. 61(6), 1413-1427.
Mitra, A., Ko, Y., Cingolani, G., & Niederweis, M. (2019). Heme and hemoglobin utilization by Mycobacterium tuberculosis. Nat. Commun. 10, 4260.
Miethke, M., & Marahiel, M. A. (2007). Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Rev. 71(3), 413-451.
Muller, G., Matzanke, B. F., & Raymond, K. N. (1984). Iron transport in Streptomyces pilosus mediated by ferrichrome siderophores, rhodotorulic acid, and enantio-rhodotorulic acid. J. Bacteriol. 160(1), 313-318.
Nagoba, B., & Vedpathak, D. (2011). Medical applications of siderophores. *Eur. J. Gen. Med.*, 8(3), 229-235.

Neilands, J. B. (1981). Microbial iron compounds. *Ann. Rev. Biochem.*, 50, 715-731.

Pal, R. B., & Gokarn, K. (2010). Siderophores and pathogenicity of microorganisms. *J. Biosci. Technol.*, 1(3), 127-134.

Perez-Miranda, S., Cabirol, N., George-Tellez, R., Zamudio-Rivera, L. S., & Fernandez, F. J. (2007). O-CAS, a fast and universal method for siderophore detection. *J. Microbiol. Method.*, 70(1), 127-131.

Petrik, M., Zhai, C., Haas, H., & Decristoforo, C. (2017). Siderophores for molecular imaging applications. *Clin. Transl. Imaging.*, 5(1), 15-27.

Pramanik, A., Stroeher, U. H., Krejci, J., Standish, A. J., Bohn, E., Paton, J. C., Autenrieth, I. B., & Braun, V. (2007). Albomycin is an effective antibiotic, as exemplified with *Yersinia enterocolitica* and *Streptococcus pneumoniae*. *Int. J. Med. Microbiol.*, 297(6), 459-469.

Poole, K., Young, L., & Neshat, S. (1990). Enterobactin-mediated iron transport in *Pseudomonas aeruginosa*. *J. Bacteriol.*, 172(12), 6991-6996.

Reedy, J. (2007). Trojan horse strategy defeats drug resistant bacteria. *J. Clin. Invest.* Available from: https://www.eurekalert.org/pub_releases/2007-03/uow-ths031507.php.

Saha, R., Saha, N., Donofrio, R. S., & Bestervelt, L. L. (2013). Microbial siderophores: a mini review. *J. Basic Microbiol.*, 53(4), 303-317.

Saha, M., Sarkar, S., Sarkar, B., Sharma, B. K., Bhattacharjee, S., & Tribedi, P. (2016). Microbial siderophores and their potential applications: a review. *Env. Sci. Poll. Res.*, 23(5), 3984-3999.

Schalk, I. J., Lamont, I. L., & Cobessi, D. (2009). Structure-function relationships in the bifunctional ferrisiderophore FpvA receptor from *Pseudomonas aeruginosa*. *Biometals.*, 22(4), 671-678.

Scott, M. D., Ranz, A., Kuypers, F. A., Lubin, B. H., & Meshnick, S. R. (1990). Parasite uptake of desferroxamine: a prerequisite for antimalarial activity. *Br. J. Haematol.*, 75(4), 598-602.

Stintzi, A., & Raymond, K. N. (2000). Amonabactin-mediated iron acquisition from transferrin and lactoferrin by *Aeromonas hydrophila*: direct measurement of individual microscopic rate constants. *J. Biol. Inorg. Chem.*, 5, 57-66.

Smith, M. J., Shoolery, J. N., Schwyn, B., Holden, I., & Neilands, J. B. (1985). Rhizobactin, a structurally novel siderophore from *Rhizobium meliloti*. *J. Am. Chem. Soc.*, 107(6), 1739-1743.

Sebbane, F., Jarrett, C., Gardner, D., Long, D., & Hinnebusch, B. J. (2010). Role of the *Yersinia pestis* Yersiniabactin iron acquisition system in the incidence of flea-borne plague. *PLoS ONE* 5(12), e14379.

Smith, M. J., & Neilands, J. B. (1984). Rhizobactin, a siderophore from *Rhizobium meliloti*. *J. Plant Nutr.*, 7(1-5), 449-458.

Shenker, M., Oliver, I., Helmann, M., Hadar, Y., & Chen, Y. (1992). Utilization by tomatoes of iron mediated by a siderophore produced by *Rhizopus arrhizus*. *J. Plant Nutr.*, 15(10), 2173-2182.

Tsafack, A., Libman, J., Shanzer, A., & Cabantchik, Z. I. (1996). Chemical determinants of antimalarial activity of reversed siderophores. *Antimicrob. Agents Chemother.*, 40, 2160-2166.

Trivedi, H. B., Vala, A. K., Dhrangadhriya, J. H., & Dave, B. P. (2016). Marine-derived fungal siderophores: a perception. *Indian J. Geo-Mar. Sci.*, 45(3), 431-439.

Torti, S. V., & Torti, F. M. (2013). Iron and cancer: more ore to be mined. *Nat. Rev. Cancer* 13(5), 342-355.
Tomaras, A. P., Crandon, J. L., McPherson, C. J., Banevicius, M. A., Finegan, S. M., Irvine, R. L., Brown, M. F., O’Donnell, J. P., & Nicolau, D. P. (2013). Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57, 4197-4207.

Visca, P., & Imperi, F. (2018). An essential transcriptional regulator: The case of Pseudomonas aeruginosa fur. Future Microbiol. 13(8), 853-856.

Vogel, A. E. (1987). Class reactions (reactions for functional groups), In: Elementary Practical Organic Chemistry, CBS Publishers, New Delhi, 190-194.

Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., & Niederweis, M. (2013). Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog. 9(1), e1003120.

Winkelmann, G. (2007). Ecology of siderophores with special reference to the fungi. Biometals 20, 379-392.

Zahner, H., Keller-Schierlein, W., Hutter, R., Hess-Leisinger, K., & Deer, A. (1963). Stoffwechselprodukte von Mikroorganismen 40. Mitteilung. Sideramine aus Aspergillaceen. Arch. Microbiol. 45, 119-135.